Joely Kaufman, MD, a Dermatologist and the Director of Skin Associates of South Florida in Coral Gables, FL, breaks down the findings of a new survey of healthcare providers that looked at the impact of glucagon-like peptide-1 (GLP-1) receptor agonist-associated weight loss on midface volume, skin laxity, and facial wrinkles/folds and shares the main aesthetic treatments used to combat these concerns. Dr. Kaufman also suggests the best time to broach conversations about these potential changes with patients taking weight loss medications. She recently presented the survey findings at the 2025 American Society for Dermatologic Surgery meeting in Chicago, IL.
